Retatrutide vs Ozempic: Triple Agonist vs the Original GLP-1
Reviewed by Peptide Nerds Editorial · Updated March 2026
Retatrutide vs Ozempic: Triple Agonist vs the Original GLP-1
Key takeaways:
- Retatrutide produced 28.7% weight loss in Phase 2 trials vs Ozempic's 14.9% in STEP 1. Nearly double.
- Ozempic targets 1 receptor (GLP-1). Retatrutide targets 3 (GLP-1, GIP, and glucagon).
- The glucagon receptor is the key differentiator. It increases energy expenditure and fat burning.
- Ozempic is FDA-approved and available now. Retatrutide is still investigational. Not yet approved.
- Both cause GI side effects. Retatrutide also shows a unique dysesthesia signal not seen with Ozempic.
- For anyone who needs treatment today, Ozempic is the practical choice. Retatrutide may become the better option once approved.
This is not medical advice. The information below is for educational purposes only. Always consult a qualified healthcare provider before starting any medication. See our full medical disclaimer.
Quick terminology check
Before we compare, let's clear up the names.
Ozempic is the brand name for semaglutide, made by Novo Nordisk. It is FDA-approved for type 2 diabetes. The weight loss version of the same drug is called Wegovy. Same molecule, different dose and indication.
Retatrutide is an investigational drug made by Eli Lilly. It has not been approved by the FDA for any indication. It is currently in Phase 3 clinical trials.
When we say "Ozempic" in this article, we are referring to semaglutide at the 2.4mg weekly dose used for weight management (the Wegovy dose). That is the dosage with the most published weight loss data.
How they work: 1 receptor vs 3
This is where the comparison gets interesting.
Ozempic (semaglutide) activates one receptor: GLP-1. This hormone slows gastric emptying, reduces appetite, and improves insulin sensitivity. It is effective. Millions of prescriptions prove that. But it is working through a single pathway.
Retatrutide activates three receptors: GLP-1, GIP, and glucagon. The GLP-1 and GIP components work similarly to tirzepatide (Mounjaro/Zepbound), which is already a dual agonist. The third receptor, glucagon, is what sets retatrutide apart from everything else in development.
Glucagon increases energy expenditure. It promotes fat oxidation. It tells your liver to burn stored energy rather than just reducing how much goes in. Semaglutide reduces input. Retatrutide reduces input AND increases output.
Think of it this way: Ozempic closes one valve. Retatrutide closes that same valve and opens a drain.
Get the Peptide Starter Kit (free)
A quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
Weight loss: the numbers
Here is the head-to-head data from published trials.
| Metric | Semaglutide 2.4mg (STEP 1) | Retatrutide 12mg (Phase 2) |
|---|---|---|
| Average weight loss | 14.9% | 28.7% |
| Trial duration | 68 weeks | 48 weeks |
| Patients losing 10%+ | 69.1% | ~93% |
| Patients losing 20%+ | 32.0% | ~75% |
| Trial size | 1,961 participants | 338 participants |
Sources: STEP 1 (NEJM, 2021), Retatrutide Phase 2 (NEJM, 2023)
The retatrutide numbers are striking. Nearly double the weight loss in a shorter trial period. And the percentage of patients hitting major weight loss milestones (20%+) is dramatically higher.
But context matters. STEP 1 was a large Phase 3 trial. The retatrutide data comes from a smaller Phase 2 study. Phase 2 results sometimes look stronger than Phase 3 results because of smaller, more controlled populations. We need to see the Phase 3 data before making definitive claims.
Still, the gap is large enough that most researchers expect retatrutide to outperform semaglutide even after Phase 3 results come in. The triple receptor mechanism provides a plausible explanation for the difference.
For a deeper look at the retatrutide data, see our retatrutide weight loss breakdown.
Side effects comparison
Both drugs cause gastrointestinal side effects. Nausea, vomiting, diarrhea, and constipation are the most common complaints with any GLP-1 based therapy.
| Side Effect | Semaglutide 2.4mg | Retatrutide 12mg |
|---|---|---|
| Nausea | 44.2% | 45.3% |
| Diarrhea | 29.7% | 24.4% |
| Vomiting | 24.8% | 18.2% |
| Constipation | 23.4% | 15.9% |
| Dysesthesia | Not reported | ~5% |
| Serious adverse events | 1.0% | Low (Phase 2) |
Sources: STEP 1, Retatrutide Phase 2
GI side effects are comparable. Retatrutide actually showed lower rates of diarrhea, vomiting, and constipation at the highest dose, despite producing much greater weight loss.
The signal unique to retatrutide is dysesthesia. This is an abnormal sensation, often described as tingling, burning, or numbness on the skin. It appeared in roughly 5% of participants at the 12mg dose. Researchers believe it may be related to glucagon receptor activation. It is generally mild and temporary, but it is something semaglutide does not cause.
The safety track record gap is real. Semaglutide has been prescribed to millions of people over several years. We have robust long-term data. Retatrutide has been tested in a few hundred people over months. Rare side effects only show up in large populations over time. That is a meaningful difference right now.
Availability: the biggest practical difference
This is the factor that matters most for anyone making a decision today.
Ozempic/Wegovy: Available now by prescription. FDA-approved. Covered by many insurance plans (though coverage varies). Compounded versions exist at lower cost, though the legal landscape around compounding is shifting.
Retatrutide: Not available. Not FDA-approved. Still in Phase 3 clinical trials. The earliest possible approval is likely late 2026 or 2027, assuming trials go well and the FDA review moves on schedule.
You cannot walk into a doctor's office and get a retatrutide prescription. If weight management is a priority for you right now, semaglutide (or tirzepatide) are your evidence-based, FDA-approved options.
For the latest on where retatrutide stands in the approval process, see our FDA approval timeline tracker.
Cost comparison
| Factor | Ozempic/Wegovy | Retatrutide (projected) |
|---|---|---|
| Monthly cost (list) | $900-1,300 | $1,000-1,500 (estimated) |
| Insurance coverage | Growing, varies by plan | Unknown (not yet approved) |
| Compounding options | Available (limited) | None |
| Savings programs | Manufacturer coupons available | None |
Semaglutide pricing has been a moving target. Insurance coverage has expanded, manufacturer savings programs exist, and compounding pharmacies offer lower-cost alternatives.
Retatrutide pricing is speculation at this point. Eli Lilly has not announced pricing. Based on the tirzepatide pricing model and the added complexity of a triple agonist, industry analysts expect it to land in the $1,000-1,500 per month range at launch.
Who should consider each option
Ozempic/semaglutide makes sense if:
- You need treatment now
- You have not tried a GLP-1 receptor agonist before
- Your insurance covers Wegovy or Ozempic
- You want a medication with years of real-world safety data
Retatrutide may make sense if:
- You have tried semaglutide or tirzepatide and plateaued
- You need greater than 15-20% weight loss
- You are willing to wait for FDA approval
- You are comfortable being among the earlier adopters of a new drug class
The progression is logical. GLP-1 alone works for many people. Dual agonists (like tirzepatide) work for those who need more. Triple agonists like retatrutide represent the next step for those who need the most aggressive intervention.
The bigger picture: the agonist progression
We are watching a clear generational progression in obesity pharmacotherapy.
Generation 1: Single agonists. Semaglutide. One receptor (GLP-1). ~15% average weight loss.
Generation 2: Dual agonists. Tirzepatide. Two receptors (GLP-1 + GIP). ~20-22% average weight loss.
Generation 3: Triple agonists. Retatrutide. Three receptors (GLP-1 + GIP + glucagon). ~28% average weight loss.
Each generation adds a receptor and produces meaningfully greater results. The glucagon receptor in particular opens up a new dimension of treatment by increasing energy expenditure, not just reducing appetite.
For a full comparison across all three generations, see our semaglutide vs tirzepatide vs retatrutide breakdown.
FAQ
Is retatrutide the same as Ozempic? No. They are different drugs made by different companies. Ozempic (semaglutide) is made by Novo Nordisk and targets one receptor. Retatrutide is made by Eli Lilly and targets three receptors. Retatrutide is not yet FDA-approved.
Can I get retatrutide right now? Not through a standard prescription. Retatrutide is only available through clinical trials. Some research peptide sources sell it, but those products are unregulated and not intended for human use. We do not recommend self-administering investigational compounds.
Is retatrutide better than Ozempic for weight loss? Based on clinical trial data, retatrutide produces significantly more weight loss. But "better" also includes safety, availability, and cost. Ozempic has a longer safety record and is available today. Retatrutide may eventually prove to be the superior weight loss drug, but it has not cleared regulatory approval yet.
Will retatrutide replace Ozempic? Unlikely to replace it entirely. Semaglutide works well for millions of people. Retatrutide will likely become an option for those who need more aggressive treatment or who do not respond adequately to GLP-1 only therapy. Both will likely coexist in the market, similar to how Ozempic and Mounjaro coexist today.
What about tirzepatide? Where does it fit? Tirzepatide (Mounjaro/Zepbound) sits between semaglutide and retatrutide. It is a dual agonist (GLP-1 + GIP), FDA-approved, and produces about 20% weight loss. For a full three-way comparison, see our semaglutide vs tirzepatide vs retatrutide guide.
Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. We share published research and editorial analysis, not medical recommendations.
Sources
- Wilding, J.P.H., et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021. PMID: 33567185
- Jastreboff, A.M., et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity." New England Journal of Medicine, 2023. PMID: 37385275
Get the Peptide Starter Kit (free)
Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.